Screener
Odyssey Therapeutics ODTX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Odyssey Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Odyssey Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 5, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335822
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| General and administrative | 10,511 | 13,219 | 17,861 | 21,171 |
| Change in fair value of contingent consideration | 8,733 | (566) | 8,842 | (6,214) |
| Total operating expenses | 55,470 | 42,880 | 95,250 | 83,958 |
| Operating loss | (55,470) | (41,921) | (95,250) | (81,081) |
| Other income (expense), net: | ||||
| Interest income | 2,832 | 872 | 4,540 | 2,028 |
| Interest expense | (20) | (2) | (30) | (4) |
| Other expense, net | (138) | (154) | (255) | (443) |
Item 1. Financial Statements.
FAQ
- What is Odyssey Therapeutics's operating income?
- Odyssey Therapeutics (ODTX) reported operating income of -$55.47M in Q2 2026.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Odyssey Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude